Radmir R. Rakhimov, Aleksandr V. Sultanbaev, Adel A. Izmailov, Konstantin V. Menshikov, Vadim M. Zabelin, Albert A. Izmailov, Gulshat R. Gilyazova, Svetlana M. Izmailova, Ksenia S. Bakhtiyarova, Angelina A. Izmailova and Irina R. Gilyazova* Pages 3312 - 3323 ( 12 )
Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms.
Method: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by applying modern target drugs and immunotherapy.
Result: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy.
Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients.
Oncology, renal cancer, immunotherapy, checkpoint inhibitors, nivolumab, ipilimumab.